Case Report

Acute Lymphoblastic Leukemia Presenting as Pituitary Apoplexy: A Case Report and Review of the Literature

Rahul Gupta,1 Urmimala Bhattacharjee,2 K. S. Lekshmon,2 Shakun Chaudhary1, Prashant Sharma,2 Aditya Jandial2, and Pinaki Dutta1

1Department of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
2Department of Clinical Hematology and Medical Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Correspondence should be addressed to Aditya Jandial; adityapgimer@gmail.com and Pinaki Dutta; drpinakidutta12@gmail.com

Received 17 October 2021; Accepted 16 December 2021; Published 28 December 2021

1.Introduction

Pituitary apoplexy (PA) is a clinical syndrome characterized by acute-onset headache caused by sudden hemorrhage and/or infarction. Precipitating factors are identified in only 20 to 40% of the cases [1]. Though the exact precipitating factor remains unidentified in majority, haemodynamic stress, pituitary stimulation test, coagulation disturbances, and thrombocytopenia are few of the reported risk factors [2]. Thrombocytopenia secondary to an underlying haematological malignancy as a precipitating event for apoplexy is uncommon. Here, we present a case of precursor B-cell lineage acute lymphoblastic leukaemia presenting with pituitary apoplexy. The patient provided written informed consent for allowing use of information and publication of images.

2. Case Presentation

A 60-year-old male presented to the emergency department with chief complaints of sudden-onset headache, vision loss in both eyes, and drooping of eyelids for the last two days. On initial evaluation, he was haemodynamically stable, conscious, and fully oriented. Positive findings on examination included bilateral absent light perception, complete external ophthalmoplegia, bilateral ptosis, optic atrophy, and gynaecomastia (Figures 1(a) and 1(b)). A noncontrast computed tomography (NCCT) scan revealed a hyperdense sellar mass (Figure 1(c)), and contrast-enhanced magnetic resonance imaging showed a 3.1 × 2.7 × 4.1 cm sellar mass with the peripheral rim of T1 hyperintensity suggestive of adenoma with an acute to early subacute bleed (Figure 1(d)). The initial pituitary hormone profile was suggestive of

Thrombocytopenia as a precipitating factor for pituitary apoplexy (PA) is very rare event. There are only five reported cases of PA secondary to thrombocytopenia caused by underlying haematological malignancy. Herein, we report a case of 60-year-old male presenting with acute-onset headache, bilateral vision loss, and ptosis. Computed tomography and magnetic resonance imaging revealed findings indicative of pituitary adenoma with apoplexy. He was noted to have thrombocytopenia, and bone marrow evaluation revealed precursor B-lineage CALLA-positive acute lymphoblastic leukaemia. Accordingly, he was started on dexamethasone and vincristine but succumbed to Acinetobacter baumanii-related hospital-acquired pneumonia two weeks after initiation of chemotherapy. We performed a literature search and found five cases of pituitary apoplexy secondary to haematological malignancy-related thrombocytopenia. The usual age of presentation was in the 6th to 7th decade, and there was slight male preponderance. The underlying pituitary adenoma was either nonfunctioning or a prolactinoma, and in majority, the apoplexy event occurred after the diagnosis of haematological malignancy. The platelet counts at the time of PA were less than 30 × 10^9/L in all, and the malignancy subtypes were acute or chronic myeloid leukemia and chronic lymphoid leukemia. The current case highlights the importance of careful evaluation for the cause of thrombocytopenia in a case of PA.
secondary hypothyroidism (T4: 3.79 ug/dl (4.8–12.7); T3: 0.804 ng/ml (0.8–2); and TSH: 7.01 uIU/ml (0.27–4.2)), secondary hypogonadism (LH: 0.270 mIU/ml; testosterone 0.0868 nmol/l (9.9–27.8); and low prolactin 3.01 ng/ml (4.0–15.2)). In view of presumptive diagnosis of apoplexy, he was started on intravenous hydrocortisone before blood sample for cortisol estimation was withdrawn, but had a normal blood pressure, serum electrolytes, and plasma glucose. In view of the pituitary apoplexy score of 6 and presence of bilateral vision loss, he was planned for urgent surgical decompression [3].

He was noted to have pancytopenia on initial complete blood count (Hb: 9.8 gm/dl; TLC: 1.7 \times 10^9/L; DLC: Ne52, Ly42, Mo06%; and Plt: 23 \times 10^9/L) for which bone marrow evaluation was performed. This revealed 70% blast cells that were cytochemically myeloperoxidase negative and on flow cytometry expressed CD19, CD10, CD81, HLA-DR, CD58, and CD38 along with cytoplasmic CD79a, CD22, and nuclear TdT. The blasts were negative for T/NK cell and myeloid lineage markers, as well as for CD86, CD34, and CD123. CD20 was dim to negative. Reverse-transcriptase PCR was negative for t (9; 22), t (1; 19), and t (12; 21). The final hematological diagnosis was precursor B-lineage CALLA-positive acute lymphoblastic leukaemia (Figure 2).

Considering his age, poor performance status, and financial limitation, he was started on dexamethasone 10 mg/m² daily and weekly vincristine 1.4 mg/m². However, our patient developed Acinetobacter baumanii-related hospital-acquired pneumonia two weeks after initiation of chemotherapy and ultimately succumbed due to refractory septic shock.
3. Review of the Literature

We performed an extensive literature search in PubMed, EMBASE, and SCOPUS using the terms “pituitary, apoplexy, and thrombocytopenia,” “pituitary, apoplexy, and leukemia,” “apoplexy and thrombocytopenia,” and “apoplexy and thromboctopenia.” We came across five cases of pituitary apoplexy associated with haematological malignancy in the English language over a period of 22 years (1996–2018, Table 1). The age at presentation was in the range of 55 years to 72 years. There was slight male preponderance with a male-to-female ratio of 3:2. At presentation, headache and vomiting were present in all while visual field abnormalities, ophthalmoplegia, altered sensorium, and meningismus were present variably. The lag time from symptom onset to diagnosis varied from 12 hours to 6 weeks. The pituitary adenoma type was either prolactinoma or nonfunctioning, and the associated haematological malignancy was either acute or chronic myeloid leukemia or chronic lymphoid leukemia. In all except one, PA occurred after the diagnosis of haematological malignancy, and the platelet count at the time of PA was less than $30 \times 10^9/L$ in all. Two of the five cases were managed conservatively and the other three with transphenoidal surgery (TSS) along with steroids. The resolution of sellar mass was seen in two cases, one managed with TSS while other conservatively (Table 1).

4. Discussion

We report a case of pituitary apoplexy secondary to thrombocytopenia caused by precursor B-cell acute lymphoblastic leukemia.

PA is characterized by sudden hemorrhagic infarction in a pituitary adenoma. This results in an increase in intrasellar pressure leading to a constellation of symptoms that often but not always comprise headache, nausea, vomiting, decreased vision, and diplopia. Rarely, it may lead to meningismus (secondary to extravasation of blood in subarachnoid space), hemiplegia, hypotension, and altered sensorium. True apoplexy (clinical symptoms plus radiological evidence of pituitary hemorrhage) is an uncommon event occurring in 2 to 10% of pituitary adenoma [1]. In a majority of the cases, the event is spontaneous; however, a precipitating cause is identified in 25–30% patients. Various precipitating causes reported include hypertension, hypotension, major surgery, head trauma, radiation, drugs

Figure 2: Lymphoblasts were rare in the peripheral blood (a) and comprised 70% of all cells in the bone marrow (b, c) (May–Grünwald–Giemsa stain, ×1000). On flow cytometry, they were CD45 negative to dim positive with low side scatter (d) and coexpressed CD19 and CD10 (e) as well as showed dim to negative CD20 expression (f).
The two major mechanisms by which these factors cause apoplexy are either by causing acute fluctuations in blood pressure or by increasing the bleeding tendency. The pituitary gland being a neuroendocrine organ has a rich venous plexus blood supply network which predisposes it to a hemorrhagic event in response to the abovementioned stressors [4].

Thrombocytopenia leading to PA is a relatively uncommon event, and in a majority of such cases, it is either idiopathic or secondary to an underlying infection such as dengue hemorrhagic fever. To the best of our knowledge, only five cases of PA resulting from a haematological malignancy-induced thrombocytopenia have been reported so far (Table 1) [5–9]. The age of presentation was from the 5th to 7th decade, and they were either prolactinoma or nonfunctioning. In a majority of them, thrombocytopenia was a consequence of chemotherapy for the underlying malignancy and all had a platelet count of less than $30 \times 10^9/L$ at presentation. Our case had a nonfunctioning pituitary adenoma and presented in the 6th decade with a platelet count of $23 \times 10^9/L$. However, it was unusual in that the apoplexy event was the presenting manifestation of an underlying haematological malignancy and highlights the importance of keeping this rare possibility in a case of PA with thrombocytopenia. Furthermore, the possibility of leukemic malignant cell infiltration into the pituitary adenoma cannot be ruled out in the current case, a rare but known event [7]. However, the presence of gynaecomastia suggestive of longstanding hypogonadism and optic atrophy indicates that pituitary adenoma has likely preceded the development of precursor B-cell lineage acute lymphoblastic leukaemia.

Another important issue pertains to the management of PA in the setting of thrombocytopenia. Both medical and surgical treatments are available for management of PA. The aim of surgery is to decrease the intrasellar pressure in order to decompress the optic chiasma and the nerves in cavernous sinus. Except in a scenario of worsening neurological status in whom surgery is indicated, at present, there is no clear recommendation as to the mode of therapy with the best outcome [3]. Furthermore, the presence of thrombocytopenia increases the perioperative risk of hemorrhagic complications. Though there are no clear recommendations for preoperative platelet count for neurosurgical procedures, the platelet count should be more than $100 \times 10^9/L$ [10].

| Author                        | N. Wongraparut et al. | Yoshinori Maki et al. | Khaled M. Krisht et al. | L. Silberstein et al. | C. C. Kingdon et al. |
|-------------------------------|-----------------------|-----------------------|-------------------------|-----------------------|----------------------|
| Age/gender                    | 72/F                  | 64/F                  | 77/M                    | 55/M                  | 61/M                 |
| Pituitary adenoma type        | Nonfunctioning        | Prolactinoma          | Prolactinoma            | Nonfunctioning        | NA                   |
| Haematological malignancy     | Acute myeloid leukaemia | Chronic myeloid leukaemia | Chronic lymphoid leukaemia | Acute myeloid leukaemia | Chronic lymphoid leukaemia |
| Diagnosis of apoplexy         | No                    | No                    | No                      | No                    | Yes                  |
| Haematological malignancy     | Acute myeloid leukaemia | Chronic myeloid leukaemia | Chronic lymphoid leukaemia | Acute myeloid leukaemia | Chronic lymphoid leukaemia |
| Platelet count                | $13 \times 10^9/L$    | $29 \times 10^9/L$    | NA                      | $19 \times 10^9/L$    | NA                   |
| Chemotherapy                  | High-dose cytarabine  | Cabergoline           | Headache, vomiting, left complete ophthalmoplegia, and diminished sensation in V1 and V2 | Headache, vomiting, fever, and meningismus | Headache, fever, and altered sensorium |
| Clinical presentation         | Headache, vomiting, b/l visual field deficit, and impairment in visual acuity | Headache, vomiting, hypotension, Rt ptosis, and Lt abducens nerve palsy | NA                      | NA                    | NA                   |
| Lag time                      | 12 hours              | NA*                   | 48 hours                | In hospital (day 6 of chemotherapy) | 6 weeks              |
| Hormone dysfunction           | Hypothyroidism; hypoprolactinemia | Hypothyroidism; hypocortisolism | Hypothyroidism | Hypocortisolism | Hypogonadism |
| Size of pituitary mass        | $1 \times 1 \times 1 \times 1 cm$ | NA                      | $4 \times 3.7 \times 3.7 cm$ | NA                    | NA                   |
| Management                    | TSS # + steroids      | TSS + steroids        | TSS + steroids          | Conservative          | Conservative         |
| Resolution of mass size       | NA                    | Yes                   | NA                      | NA                    | NA                   |
| Resolution of 1. Visual field deficit | NA                     | NA                    | NA                      | NA                    | NA                   |
| Resolution of 2. Visual acuity deficit | Improved              | Improved              | NA                      | NA                    | NA                   |
| Resolution of 3. Ocular paresis | NA                    | Resolved              | Improved               | NA                    | NA                   |

*NA: not available; #TSS: transphenoidal surgery.

(bromocriptine, cabergoline, antiplatelet agents, and anti-coagulants), endocrine anterior pituitary stimulation test, and thrombocytopenia [4].
regard to long-term outcomes following endoscopic endonasal surgery, improvement in visual field and cranial nerve paresis is seen in 70 to 90% of the cases while hypopituitarism persists in majority [11–13]. Hence, one needs to balance the risk of perioperative hemorrhagic complications with that of uncertain long-term benefits of surgery in a case of PA with thrombocytopenia. In our patient, persistent thrombocytopenia despite platelet transfusion, intact sensorium, an improving external ophthalmoplegia, and vision in response to dexamethasone made us decide in favour of medical management. In this regard, a comprehensive evaluation by a team comprising of endocrinologists, haematologists, and neurosurgeons is of utmost importance for timely diagnosis and optimal patient outcome.

5. Conclusions

In a case of pituitary apoplexy associated with thrombocytopenia, a systematic evaluation for the cause of the latter is required. The selection of the management modality in such cases should balance the risk of perioperative hemorrhagic complications with that of uncertain long-term benefits of surgery, and such cases are likely to be better managed by a multidisciplinary team.

Data Availability

The datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

Disclosure

Rahul Gupta and Urmimala Bhattacharjee are co-first authors.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] R. N. Nawar, D. AbdelMannan, W. R. Selman, and B. M. Arafa, "Analytic review: pituitary tumor apoplexy: a review," Journal of Intensive Care Medicine, vol. 23, no. 2, pp. 75–90, 2008.
[2] C. Briet, S. Salenave, J.-F. Bonneville, E. R. Laws, and P. Chanson, "Pituitary apoplexy," Endocrine Reviews, vol. 36, no. 6, pp. 622–645, 2015.
[3] S. Rajasekaran, M. Vanderpump, S. Baldeweg et al., “UK guidelines for the management of pituitary apoplexy,” Clinical Endocrinology, vol. 74, no. 1, pp. 9–20, 2011.
[4] S. Murad-Kebou and E. Eggenberger, "Pituitary apoplexy: evaluation, management, and prognosis," Current Opinion in Ophthalmology, vol. 20, no. 6, pp. 456–461, 2009.
[5] N. Wongpraparat, N. Pleanboonlers, P. Suwattee et al., "Pituitary apoplexy in a patient with acute myeloid leukemia," Pituitary, vol. 3, no. 2, pp. 113–116, 2000.
[6] Y. Maki, Y. Kuroski, K. Uchino, R. Ishibashi, M. Chin, and S. Yamagata, “Pituitary apoplexy in long-term cabergoline user during thrombocytopenia due to chemotherapy for chronic myelocytic leukemia,” World Neurosurgery, vol. 120, pp. 290–295, 2018.
[7] K. M. Krisht, C. A. Palmer, and W. T. Couldwell, “Combined chronic lymphocytic leukemia and prolactinoma: a rare occurrence in a patient presenting with pituitary apoplexy,” Journal of Neurosurgery, vol. 119, no. 4, pp. 924–928, 2013.
[8] L. Silberstein, C. Johnston, A. Bhagat, L. Tibi, and J. Harrison, “Pituitary apoplexy during induction chemotherapy for acute myeloid leukemia,” British Journal of Haematology, vol. 143, no. 2, p. 151, 2008.
[9] C. Kingdon, P. Sidhu, and J. Cohen, “Pituitary apoplexy secondary to an underlying abscess,” Journal of Infection, vol. 33, no. 1, pp. 53–55, 1996.
[10] D. Li, T. Glor, and G. A. Jones, “Thrombocytopenia and neurosurgery: a literature review,” World Neurosurgery, vol. 106, pp. 277–280, 2017.
[11] D. J. Pangal, K. Chesney, Z. Memel et al., “Pituitary apoplexy case series: outcomes after endoscopic endonasal transsphenoidal surgery at a single tertiary center,” World Neurosurgery, vol. 137, pp. e366–e372, 2020.
[12] M. Zoli, L. Milanese, M. Faustini-Fustini et al., “Endoscopic endonasal surgery for pituitary apoplexy: evidence on a 75-case series from a tertiary care center,” World Neurosurgery, vol. 106, pp. 331–338, 2017.
[13] J. A. Gondim, L. A. F. de Albuquerque, J. P. Almeida et al., "Endoscopic endonasal surgery for treatment of pituitary apoplexy: 16 years of experience in a specialized pituitary center," World Neurosurgery, vol. 108, pp. 137–142, 2017.